AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

67.71USD
19 Dec 2014
Price Change (% chg)

$-0.21 (-0.31%)
Prev Close
$67.92
Open
$67.78
Day's High
$68.62
Day's Low
$66.86
Volume
5,597,661
Avg. Vol
2,375,273
52-wk High
$70.76
52-wk Low
$45.51

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. The Company’s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease, and complications associated with... (more)

Overall

Beta: --
Market Cap (Mil.): $107,892.60
Shares Outstanding (Mil.): 1,593.45
Dividend: 0.49
Yield (%): 2.89

Financials

  ABBV.N Industry Sector
P/E (TTM): 29.35 37.83 38.47
EPS (TTM): 2.31 -- --
ROI: 17.19 18.99 18.25
ROE: 90.29 19.75 19.13
Search Stocks

U.S. FDA approves AbbVie all-oral hepatitis C treatment

- U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.

5:17am IST

UPDATE 1-U.S. FDA approves AbbVie all-oral hepatitis C treatment

Dec 19 - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.

1:58am IST

U.S. FDA approves AbbVie all-oral hepatitis C treatment

Dec 19 - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.

1:32am IST

Shire considering bid for NPS Pharmaceuticals: Bloomberg

- Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

18 Dec 2014

Deals of the day- Mergers and acquisitions

(Adds Shire, Carrefour, Clessidra, CMVM, Snam, Eni, Lala, Lucchini and KGHM)

18 Dec 2014

Shire considering bid for NPS Pharmaceuticals: Bloomberg

- Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

Shire considering bid for NPS Pharmaceuticals - Bloomberg

Dec 17 - Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

Shire CEO eyes deals, but no urgency to spend AbbVie breakup fee

NEW YORK - Shire PLC's chief executive said he sees no urgency to spend the windfall the Dublin-based drugmaker received when AbbVie walked away from a $55 billion takeover bid earlier this year.

11 Dec 2014

India's Cadila launches first cheaper copy of world's top-selling drug

MUMBAI - Indian drugmaker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its U.S. price.

09 Dec 2014

Europe gives green light to AbbVie hepatitis C drugs, others

LONDON - European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe.

21 Nov 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $105.55 -1.26
Pfizer Inc. (PFE.N) $31.94 -0.03
Novartis AG (NOVN.VX) CHF93.05 +0.95
Merck & Co., Inc. (MRK.N) $59.58 +0.60
Roche Holding Ltd. (ROG.VX) CHF270.40 -18.30
Abbott Laboratories (ABT.N) $46.05 +0.28
Eli Lilly and Co (LLY.N) $72.40 -0.05

Earnings vs. Estimates

Search Stocks